BeiGene
BGNE
#919
Rank
HK$156.68 B
Marketcap
HK$1,432
Share price
0.49%
Change (1 day)
29.31%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Annual Reports

Thumbnail BeiGene
 Annual Report 2023

Annual Report 2023

Language: English

View Annual Report
Thumbnail BeiGene
 Annual Report 2022

Annual Report 2022

Language: English

View Annual Report
Thumbnail BeiGene
 Annual Report 2021

Annual Report 2021

Language: English

View Annual Report
Thumbnail BeiGene
 Annual Report 2020

Annual Report 2020

Language: English

View Annual Report
Thumbnail BeiGene
 Annual Report 2019

Annual Report 2019

Language: English

View Annual Report
Thumbnail BeiGene
 Annual Report 2018

Annual Report 2018

Language: English

View Annual Report
Thumbnail BeiGene
 Annual Report 2017

Annual Report 2017

Language: English

View Annual Report
Thumbnail BeiGene
 Annual Report 2016

Annual Report 2016

Language: English

View Annual Report